Although the improved overall survival is significant, the prognosis of GBM is still bleak with a median survival of only 14.6 months (12.6 and 23.4 months in the MGMT-unmethylated and MGMT-methylated subgroups, respectively) [38]. The gene discussed is MGMT; the disease is glioblastoma.